ABT-737, the first authentic BH3 mimetic, was developed to selectively inhibit BCL-2, BCL-XL and BCL-W, and showed promising activity against lymphoma and small-cell lung carcinoma mouse xenograft models, providing proof of principle for this therapeutic approach [107]. Here, BCL2L1 is linked to small cell lung carcinoma.